BC Week In Review | Mar 1, 2019
Company News

Bausch wins $195M bid to acquire bankrupt Synergy's assets

Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) won a $195 million bid to acquire assets of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) in a court-supervised bankruptcy auction. Synergy markets gastrointestinal drug Trulance plecanatide. Trulance is an uroguanylin analog...
BC Week In Review | Dec 8, 2014
Clinical News

SP-333: Phase II data

Top-line data from a double-blind Phase II trial in 289 patients with OIC taking opioid analgesics for chronic, non-cancer pain for =3 months showed that once-daily 3 and 6 mg oral SP-333 for 4 weeks...
BC Week In Review | Jul 28, 2014
Clinical News

SP-333: Completed Phase II enrollment

Synergy completed enrollment of about 260 patients with OIC taking opioid analgesics for chronic, non-cancer pain for >=3 months in a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333...
BC Week In Review | Nov 11, 2013
Clinical News

SP-333: Phase II started

Synergy began a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333 once daily for 4 weeks in about 260 OIC patients taking opioid analgesics for chronic, non-cancer pain for...
BC Week In Review | Oct 7, 2013
Clinical News

SP-333: Phase II start

This quarter, Synergy will start a dose-ranging Phase II trial to evaluate once-daily oral SP-333 for 4 weeks in OIC patients taking opioid analgesics for chronic, non-cancer pain for >=3 months. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP),...
BC Week In Review | Feb 4, 2013
Clinical News

SP-333: Phase I started

Synergy began a placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate multiple doses of SP-333 in 64 healthy adults. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y.   Product: SP-333   Business: Autoimmune   Molecular target:...
BC Week In Review | Jan 7, 2013
Clinical News

SP-333: Phase I data

Top-line data from a placebo-controlled, dose-escalation, U.S. Phase I trial in about 56 healthy volunteers showed that single doses of SP-333 ranging from 0.1-60 mg did not produce any serious or unexpected adverse events. Synergy,...
BC Week In Review | Oct 29, 2012
Clinical News

SP-333: Phase I started

Synergy began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of 0.1, 0.3, 1, 3, 10, 30 and 60 mg oral SP-333 in about 56 healthy volunteers. Synergy said a multiple-dose Phase...
BC Week In Review | Jul 30, 2012
Company News

Callisto, Synergy deal

Synergy will acquire its principal stockholder Callisto in a stock deal. The deal values Callisto at $117 million based on Synergy's close of $4.34 on July 20, before the deal was announced. Each Callisto common...
Items per page:
1 - 9 of 9